Swiss Nuclides, a developer of novel radionuclide Pet tracers for the precision diagnostics, has closed the first tranche of its series A financing round, raising CHF 2.6 million from private investors. Vischer has been acting as
Swiss Nuclides, a developer of novel radionuclide Pet tracers for the precision diagnostics, has closed the first tranche of its series A financing round, raising CHF 2.6 million from private investors. Vischer has been acting as